First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)”

Jakob, Carolin E. M.; Borgmann, Stefan; Duygu, Fazılet; Behrends, Uta; Hower, Martin; Merle, Uta; Friedrichs, Anette; Tometten, Lukas; Hanses, Frank; Jung, Norma; Rieg, Siegbert; Wille, Kai; Grüner, Beate; Klinker, Hartwig; Gersbacher-Runge, Nicole; Hellwig, Kerstin; Eberwein, Lukas; Dolff, Sebastian; Rauschning, Dominic; Bergwelt‐Baildon, Michael von; Lanznaster, Julia; Strauß, Richard; Trauth, Janina; With, Katja de; Ruethrich, Maria Madeleine; Lueck, Catherina; Nattermann, Jacob; Tscharntke, Lene; Pilgram, Lisa; Fuhrmann, Sandra; Claßen, Annika Y.; Stecher, Melanie; Schons, Maximilian; Spinner, Christoph D.; Vehreschild, Jörg Janne

doi:10.1007/s15010-020-01499-0

Cited by 60 publications

(82 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In that respect, the cohort evaluated here differs from other n.s. not significant published cohorts of patients with COVID-19 [17]. Determining the detailed natural course of anti-SARS-CoV-2 antibody titers in these convalescents with mostly relatively mild COVID-19 is of major relevance for estimating the long-term duration of protective immunity against SARS-CoV-2 in this constantly exposed, highly system relevant occupational group, and also for future comparisons with vaccination-induced immune responses in populations with few comorbidities.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19

et al. 2021

View full text Add to dashboard Cite

Objective To follow serological immune responses of front-line healthcare workers after PCR-confirmed COVID-19 for a mean of 30 weeks, describe the time-course of SARS-CoV-2 spike protein-specific IgG, IgA and IgM levels and to identify associations of the immune response with symptoms, demographic parameters and severity of disease. Methods Anti-SARS-CoV-2 S protein-specific IgG, IgA and IgM antibodies were measured at three time points during the 30-week follow-up. COVID-19-specific symptoms were assessed with standardized questionnaires. Results 95% of the participants mounted an IgG response with only modest decline after week 12. IgG-type antibodies were still detectable in almost 90% of the subjects at 30 weeks. IgA and IgM responses were less robust and antibody titers decreased more rapidly. At 30 weeks, only 25% still had detectable IgA-type and none had IgM-type antibodies. Higher age and higher disease severity were independently associated with higher IgG antibody levels, albeit with wide variations. Conclusion Serological immune responses after COVID-19 show considerable inter-individual variability, but show an association with increasing age and higher severity of disease. IgG-type anti-SARS-CoV-2 antibodies remain positive in 90% of the individuals 30 weeks after onset of symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Primarily the selection bias as suggested for example by the high case fatality rate (e.g. Zhou et al [11], 28.3%, Chen et al [115] 11.1%, and Huang et al [12] 14.6%) is likely to have impacted our results and prospective data collection to confirm findings of these studies is important [116]. In addition, we found a large number of studies (n=21, list available in supplementary file S3) that included laboratory values that were obviously incorrect, which suggests that despite peer-review in some of them, the rush of publication in this pandemic impacted the quality of reporting [117].…”

Section: Discussionmentioning

confidence: 99%

Can we predict the severe course of COVID-19 – a systematic review and meta-analysis of indicators of clinical outcome?

Katzenschlager

Zimmer

Gottschalk

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundCOVID-19 has been reported in over 40million people globally with variable clinical outcomes. In this systematic review and meta-analysis, we assessed demographic, laboratory and clinical indicators as predictors for severe courses of COVID-19.MethodsWe systematically searched multiple databases (PubMed, Web of Science Core Collection, MedRvix and bioRvix) for publications from December 2019 to May 31st 2020. Random-effects meta-analyses were used to calculate pooled odds ratios and differences of medians between (1) patients admitted to ICU versus non-ICU patients and (2) patients who died versus those who survived. We adapted an existing Cochrane risk-of-bias assessment tool for outcome studies.ResultsOf 6,702 unique citations, we included 88 articles with 69,762 patients. There was concern for bias across all articles included. Age was strongly associated with mortality with a difference of medians (DoM) of 13.15 years (95% confidence interval (CI) 11.37 to 14.94) between those who died and those who survived. We found a clinically relevant difference between non-survivors and survivors for C-reactive protein (CRP; DoM 69.10, CI 50.43 to 87.77), lactate dehydrogenase (LDH; DoM 189.49, CI 155.00 to 223.98), cardiac troponin I (cTnI; DoM 21.88, CI 9.78 to 33.99) and D-Dimer (DoM 1.29mg/L, CI 0.9 - 1.69). Furthermore, cerebrovascular disease was the co-morbidity most strongly associated with mortality (Odds Ratio 3.45, CI 2.42 to 4.91) and ICU admission (Odds Ratio 5.88, CI 2.35 to 14.73).DiscussionThis comprehensive meta-analysis found age, cerebrovascular disease, CRP, LDH and cTnI to be the most important risk-factors in predicting severe COVID-19 outcomes and will inform decision analytical tools to support clinical decision-making.SummaryIn this systematic review we meta-analyzed 88 articles for risk factors of ICU admission and mortality in COVID-19. We found age, cerebrovascular disease, CRP, LDH and cTnI are the most important risk-factors for ICU admission or mortality.

show abstract

Section: Empfehlungunclassified

S2k-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19

et al. 2021

View full text Add to dashboard Cite

ZusammenfassungSeit Dezember 2019 verbreitet sich das neuartige Coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome – Corona Virus-2) rasch im Sinne einer weltweiten Pandemie. Dies stellt Kliniker und Krankenhäuser vor große Herausforderungen und belastet die Gesundheitssysteme vieler Länder in einem nie dagewesenen Ausmaß. Die Mehrheit der Patienten mit Coronavirus Disease 2019 (COVID-19) zeigt lediglich milde Symptome wie Husten und Fieber. Allerdings benötigen etwa 8 % eine stationäre Behandlung. Der frühzeitigen Klärung, ob eine stationäre und ggfs. intensivmedizinische Behandlung medizinisch sinnvoll und vom Patienten gewollt ist, kommt in der Pandemie eine besondere Bedeutung zu. Die akute hypoxämische respiratorische Insuffizienz mit Dyspnoe und hoher Atemfrequenz (> 30/min) führt i. d. R. zur Aufnahme auf die Intensivstation. Oft finden sich dann bereits bilaterale pulmonale Infiltrate/Konsolidierungen oder auch Lungenembolien in der Bildgebung. Im weiteren Verlauf entwickeln einige dieser Patienten ein akutes Lungenversagen (Acute Respiratory Distress Syndrome; ARDS). Eine Sterblichkeitsreduktion einer verfügbaren medikamentösen Therapie bei schwerer COVID-19-Erkrankung ist bisher lediglich für Dexamethason in randomisiert, kontrollierten Studien nachgewiesen. Das Hauptziel der supportiven Therapie besteht in der Sicherstellung einer ausreichenden Oxygenierung. Die invasive Beatmung und wiederholte Bauchlagerung sind dabei wichtige Elemente in der Behandlung von schwer hypoxämischen COVID-19-Patienten. Die strikte Einhaltung der Basishygiene, einschließlich der Händehygiene, sowie das korrekte Tragen von adäquater persönlicher Schutzausrüstung sind im Umgang mit den Patienten unabdingbar. Medizinisch notwendige Handlungen am Patienten, die zur Aerosolbildung führen könnten, sollten mit äußerster Sorgfalt und Vorbereitung durchgeführt werden.

show abstract

First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)”

Cited by 60 publications

References 36 publications

SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19

SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19

Can we predict the severe course of COVID-19 – a systematic review and meta-analysis of indicators of clinical outcome?

S2k-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19

Contact Info

Product

Resources

About